Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel

David Wang,Chris Jackson,Noelyn Hung,Tak Hung,Rudolf Kwan,Wing-Kai Chan,Albert Qin,Natalie J. Hughes-Medlicott,Paul Glue,Stephen Duffull

DOI: https://doi.org/10.1007/s10928-024-09913-y

2024-03-21

Journal of Pharmacokinetics and Pharmacodynamics

Abstract:The development of optimized dosing regimens plays a crucial role in oncology drug development. This study focused on the population pharmacokinetic modelling and simulation of docetaxel, comparing the pharmacokinetic exposure of oral docetaxel plus encequidar (oDox + E) with the standard of care intravenous (IV) docetaxel regimen. The aim was to evaluate the feasibility of oDox + E as a potential alternative to IV docetaxel. The article demonstrates an approach which aligns with the FDA's Project Optimus which aims to improve oncology drug development through model informed drug development (MIDD). The key question answered by this study was whether a feasible regimen of oDox + E existed. The purpose of this question was to provide an early GO / NO-GO decision point to guide drug development and improve development efficiency. Methods: A stepwise approach was employed to develop a population pharmacokinetic model for total and unbound docetaxel plasma concentrations after IV docetaxel and oDox + E administration. Simulations were performed from the final model to assess the probability of target attainment (PTA) for different oDox + E dose regimens (including multiple dose regimens) in relation to IV docetaxel using AUC over effective concentration (AUCOEC) metric across a range of effective concentrations (EC). A Go / No-Go framework was defined—the first part of the framework assessed whether a feasible oDox + E regimen existed (i.e., a PTA ≥ 80%), and the second part defined the conditions to proceed with a Go decision. Results: The overall population pharmacokinetic model consisted of a 3-compartment model with linear elimination, constant bioavailability, constant binding mechanics, and a combined error model. Simulations revealed that single dose oDox + E regimens did not achieve a PTA greater than 80%. However, two- and three-dose regimens at 600 mg achieved PTAs exceeding 80% for certain EC levels. Conclusion: The study demonstrates the benefits of MIDD using oDox + E as a motivating example. A population pharmacokinetic model was developed for the total and unbound concentration in plasma of docetaxel after administration of IV docetaxel and oDox + E. The model was used to simulate oDox + E dose regimens which were compared to the current standard of care IV docetaxel regimen. A GO / NO-GO framework was applied to determine whether oDox + E should progress to the next phase of drug development and whether any conditions should apply. A two or three-dose regimen of oDox + E at 600 mg was able to achieve non-inferior pharmacokinetic exposure to current standard of care IV docetaxel in simulations. A Conditional GO decision was made based on this result and further quantification of the "effective concentration" would improve the ability to optimise the dose regimen.

pharmacology & pharmacy

What problem does this paper attempt to address?

The paper attempts to address the feasibility of evaluating oral docetaxel plus encequidar (oDox + E) as an alternative to the standard intravenous docetaxel (IV docetaxel) regimen. Specifically:

1. **Research Objective**: To compare the pharmacokinetic exposure of oral docetaxel plus encequidar with standard intravenous docetaxel through population pharmacokinetic modeling and simulation, and to assess whether the former can serve as a potential alternative.

2. **Key Issue**: The core issue of the study is whether there is a feasible oDox + E dosing regimen. The purpose of this question is to provide an early decision point for drug development, guide drug development, and improve efficiency.

3. **Methods**: A stepwise approach was used to develop a population pharmacokinetic model for total and free docetaxel plasma concentrations, and the final model was used to evaluate the probability of target attainment (PTA) of different oDox + E dosing regimens relative to intravenous docetaxel in terms of the area under the curve at effective concentrations (AUCOEC). A Go / No-Go framework was defined to determine whether oDox + E should proceed to the next stage of drug development and to identify any applicable conditions.

4. **Conclusion**: The study showed that a single-dose oDox + E regimen failed to achieve greater than 80% PTA, but two or three dose regimens (each 600 mg) achieved over 80% PTA at certain effective concentration levels. Therefore, a conditional go decision was made based on this result, and further quantification of "effective concentration" was recommended to optimize the dosing regimen.